Scholar Rock Holding SRRK 深 沪
等待开盘 05-19 09:30:00 美东时间
47.38
-1.970
-3.99%
华盛通- 最 高49.54
- 今 开49.23
- 成交量 90.98万股
- 最 低 46.62
- 昨 收 49.35
- 总市值 56.77亿
- 52周最高 51.625
- 市盈率 静 --
- 换手率 0.76%
- 52周最低 27.07
- 委 比 99.43%
- 总股本 1.20亿
- 历史最高 70.00
- 量 比 0.60
- 振 幅 5.92%
- 历史最低 4.325
- 每 手 1
- 风险率 6.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Scholar Rock Charts Path to Apitegromab Approval
Scholar Rock Holding (($SRRK)) has held its Q1 earnings call. Read on for the m...
05-09 09:15
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $65
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $58 to $65.
05-08 19:20
Scholar Rock Advances Apitegromab Toward Potential 2026 Launches
Scholar Rock Holding ( ($SRRK) ) has shared an announcement. Scholar Rock on Ma...
05-07 19:58
财报速睇 | Scholar Rock Holding 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损1.06亿美元，同比亏损扩大41.2%
华盛资讯5月7日讯，Scholar Rock Holding公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损1.06亿美元，同比亏损扩大41.2%。
05-07 19:48
财报速睇 | Scholar Rock Holding 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损1.06亿美元，同比亏损扩大41.2%
华盛资讯5月7日讯，Scholar Rock Holding公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损1.06亿美元，同比亏损扩大41.2%。
05-07 19:34
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
Canaccord Genuity Initiates Coverage On Scholar Rock Holding with Buy Rating, Announces Price Target of $62
Canaccord Genuity analyst Gary Nachman initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Buy rating and announces Price Target of $62.
04-21 23:50
美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
U.S. RESEARCH ROUNDUP- Asana, PPG Industries, Verisign
U.S. RESEARCH ROUNDUP- Asana, PPG Industries, Verisign April 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Asana, PPG Industries and Verisign on Wednesday. HIGHLIGHTS * Asana Inc ASAN.N : RBC raises to sector perform
04-01 15:57
